OncoMatch/Clinical Trials/NCT07085169
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Is NCT07085169 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trifluridine/tipiracil (TAS-102) plus bevacizumab for colo-rectal cancer.
Treatment: Trifluridine/tipiracil (TAS-102) plus bevacizumab — This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: any chemotherapy
had received two or more previous chemotherapy regimens or intolerance to last regimen
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1.5x109/l, white blood count ≥3.5x109/l, platelets ≥75x109/l, hemoglobin (hb) ≥80g/l
Kidney function
serum creatinine ≤1.5x uln
Liver function
alt/ast ≤2.5x uln (for patient with liver metastasis alt/ast ≤5x uln), serum bilirubin ≤1.5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify